Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.75% | 8.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.75% | 8.06% | |||
| Cost of Revenue | -2.75% | -4.47% | |||
| Gross Profit | -2.75% | 17.76% | |||
| SG&A Expenses | -2.75% | 18.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | 7.72% | |||
| Operating Income | 2.75% | 4.26% | |||
| Income Before Tax | 2.75% | 87.01% | |||
| Income Tax Expenses | -2.75% | 131.13% | |||
| Earnings from Continuing Operations | 2.75% | 79.30% | |||
| Earnings from Discontinued Operations | 2.75% | -1.02% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | 74.95% | |||
| EBIT | 2.75% | 4.26% | |||
| EBITDA | -2.75% | 2.68% | |||
| EPS Basic | 2.77% | 75.02% | |||
| Normalized Basic EPS | 2.80% | 27.31% | |||
| EPS Diluted | 2.77% | 75.06% | |||
| Normalized Diluted EPS | 2.80% | 27.31% | |||
| Average Basic Shares Outstanding | 0.00% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||